Advanz Pharma’s Acquisition of Intercept Pharmaceuticals

In UK White & Case, advised on the matter.

White & Case advised ADVANZ PHARMA Corp. with a team including Marc Israel (Competition Law), Michael Weir (Picture – Corporate M&A), Nicholas Greenacre (Executive Compensation), Will Smith (Tax M&A and Deal Advisory).

Advanz Pharma announced its acquisition of the ex-US business of Intercept Pharmaceuticals. 

ADVANZ PHARMA is a specialty pharmaceutical company headquartered in London, with an operations centre of excellence in Mumbai, commercial affiliates in North America, Europe and Australia, and an established global network of commercial partners throughout the rest of the world. With an agile and experienced team, including direct sales, marketing and medical capability across many of Europe’s major markets, ADVANZ PHARMA supplies, innovates and enhances the critical medicines patients depend on, ensuring continued patient access and improving health outcomes.

Intercept Pharmaceuticals is a biopharmaceutical company focused on the development and commercialisation of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). Founded in 2002 in New York, Intercept Pharmaceuticals has operations in the United States, Europe and Canada. 

The transaction is actively supported by ADVANZ PHARMA’s owner Nordic Capital, a leading private equity investor with extensive experience and expertise in the global healthcare market, which acquired ADVANZ PHARMA in June 2021.

The White & Case team that advised on the transaction was led by partners Mike Weir (Picture; London) and Andres Liivak (New York), with support from partners Philip Abelson (New York), Marc Israel, Nicholas Greenacre, Will Smith (all London), Tilman Kuhn (Dusseldorf, Brussels), Tomislav Vrabec (Frankfurt), Alexis Hojabr, Alexandre Jaurett (both Paris) and Alessandro Seganfreddo (Milan), local partners Carlos Daroca (Madrid) and Thilo-Maximilian Wienke (Dusseldorf), and associates James Turner, Ruth Taylor, Luc Rosenberg, Kate Russell, Yannis Lagdani, Emma Jell (all London), Ajita Shukla (Washington, DC), Nashel Jung (New York), Cristina Caroppo (Dusseldorf), Eojin Lie (Frankfurt), Clement Cenreaud, Dany Luu, Dorian Smida (all Paris), Sara Scapin, Lorenza Fici (both Milan), Laura del Olmo and Gracia Truan (both Madrid).

Involved fees earner: Philip Abelson – White & Case; Cristina Caroppo – White & Case; Carlos Daroca – White & Case; Laura del Olmo – White & Case; Lorenza Fici – White & Case; Nicholas Greenacre – White & Case; Alexis Hojabr – White & Case; Marc Israel – White & Case; Alexandre Jaurett – White & Case; Emma Jell – White & Case; Nashel Jung – White & Case; Tilman Kuhn – White & Case; Eojin Lie – White & Case; Andres Liivak – White & Case; Dany Luu – White & Case; Luc Rosenberg – White & Case; Kate Russell – White & Case; Sara Scapin – White & Case; Alessandro Seganfreddo – White & Case; Ajita Shukla – White & Case; Will Smith – White & Case; Ruth Taylor – White & Case; Gracia Truan – White & Case; James Turner – White & Case; Tomislav Vrabec – White & Case; Michael Weir – White & Case; Thilo-Maximilian Wienke – White & Case;

Law Firms: White & Case;

Clients: ADVANZ PHARMA Corp.;

Author: Giulia Di Palma